Literature DB >> 9264293

Brain proton magnetic resonance spectroscopy in HIV-related encephalopathy: identification of evolving metabolic patterns in relation to dementia and therapy.

A M Salvan1, J Vion-Dury, S Confort-Gouny, F Nicoli, S Lamoureux, P J Cozzone.   

Abstract

Proton MRS has proved useful in the early diagnosis of HIV-related encephalopathy. The modifications of brain metabolism in HIV-related encephalopathy can be classified according to different metabolic patterns (Vion-Dury J et al. CR Acad Sci 1994;317:833-840). The present study describes the relative occurrence of these patterns and evaluates their evolution under zidovudine treatment. We have examined 112 HIV patients--35 neuroasymptomatic patients and 77 patients with ADC (AIDS dementia complex)--with localized proton MRS, using the PRESS 135-msec sequence. We have found the same metabolic modifications in N-acetylaspartate and choline-containing compounds as described in the literature. In addition, 14% of HIV patients with normal MRI displayed abnormal MRS, whatever their neurological status. The MRS-added diagnostic value in neuroasymptomatic patients reaches 30 %. The occurrence of undifferentiated (modification of NAA/Cho ratio only) and Cho (mainly an increase in choline signal) patterns is not significantly different in neuroasymptomatic and ADC patients. The NAA pattern (mainly a significant loss of NAA) is more frequent in ADC patients. Only ADC patients display the double pattern (with a significant increase in choline signal and a significant loss of NAA). Quantitated cerebral atrophy (bifrontal ratio) is related to the occurrence of NAA loss (in NAA and double patterns). An MRS follow-up study of 11 HIV patients showed that the clinical outcome was favorable after a 1000-mg/day zidovudine treatment in patients displaying an NAA pattern whereas this treatment had no effect on the patients displaying the Cho pattern. Consequently, MRS appears to be of great interest in predicting responsiveness to antiretroviral drugs and detecting early any resistance to treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264293     DOI: 10.1089/aid.1997.13.1055

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  18 in total

1.  Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.

Authors:  Brian C Schweinsburg; Michael J Taylor; Omar M Alhassoon; Raul Gonzalez; Gregory G Brown; Ronald J Ellis; Scott Letendre; John S Videen; J Allen McCutchan; Thomas L Patterson; Igor Grant
Journal:  J Neurovirol       Date:  2005-08       Impact factor: 2.643

2.  CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Authors:  T J Barber; A Imaz; M Boffito; J Niubó; A Pozniak; R Fortuny; J Alonso; N Davies; S Mandalia; D Podzamczer; B Gazzard
Journal:  J Neurovirol       Date:  2017-12-26       Impact factor: 2.643

3.  Exploring the relationship of macrophage colony-stimulating factor levels on neuroaxonal metabolism and cognition during chronic human immunodeficiency virus infection.

Authors:  Margaret R Lentz; Mahaveer Degaonkar; Mona A Mohamed; Hyun Kim; Katherine Conant; Elkan F Halpern; Ned Sacktor; Peter B Barker; Martin G Pomper
Journal:  J Neurovirol       Date:  2010-10       Impact factor: 2.643

4.  Central nervous system viral invasion and inflammation during acute HIV infection.

Authors:  Victor Valcour; Thep Chalermchai; Napapon Sailasuta; Mary Marovich; Sukalaya Lerdlum; Duanghathai Suttichom; Nijasri C Suwanwela; Linda Jagodzinski; Nelson Michael; Serena Spudich; Frits van Griensven; Mark de Souza; Jerome Kim; Jintanat Ananworanich
Journal:  J Infect Dis       Date:  2012-05-02       Impact factor: 5.226

5.  Longitudinal cerebral metabolic changes in pig-tailed macaques infected with the neurovirulent virus SIVsmmFGb.

Authors:  Chun-Xia Li; Xiaodong Zhang; Amelia Komery; Yingxia Li; Hui Mao; James G Herndon; Francis J Novembre
Journal:  J Neurovirol       Date:  2014-11-07       Impact factor: 2.643

6.  HIV-associated CD4+/CD8+ depletion in infancy is associated with neurometabolic reductions in the basal ganglia at age 5 years despite early antiretroviral therapy.

Authors:  Kenneth K Mbugua; Martha J Holmes; Mark F Cotton; Eva-Maria Ratai; Francesca Little; Aaron T Hess; Els Dobbels; Andre J W Van der Kouwe; Barbara Laughton; Ernesta M Meintjes
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

7.  Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.

Authors:  Eva-Maria Ratai; Jeffrey P Bombardier; Chan-Gyu Joo; Lakshmanan Annamalai; Tricia H Burdo; Jennifer Campbell; Robert Fell; Reza Hakimelahi; Julian He; Patrick Autissier; Margaret R Lentz; Elkan F Halpern; Eliezer Masliah; Kenneth C Williams; Susan V Westmoreland; R Gilberto González
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

8.  Neuronal-Glia Markers by Magnetic Resonance Spectroscopy in HIV Before and After Combination Antiretroviral Therapy.

Authors:  Napapon Sailasuta; Jintanat Ananworanich; Sukalaya Lerdlum; Pasiri Sithinamsuwan; James L K Fletcher; Somporn Tipsuk; Mantana Pothisri; Tanate Jadwattanakul; Supunnee Jirajariyavej; Thep Chalermchai; Stephanie Catella; Edgar Busovaca; Akash Desai; Robert Paul; Victor Valcour
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

9.  Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia.

Authors:  Malcolm J Avison; Avindra Nath; Robin Greene-Avison; Frederick A Schmitt; Rodney A Bales; As'ad Ethisham; Richard N Greenberg; Joseph R Berger
Journal:  J Neurovirol       Date:  2004-08       Impact factor: 2.643

10.  Selegiline and oxidative stress in HIV-associated cognitive impairment.

Authors:  G Schifitto; C T Yiannoutsos; T Ernst; B A Navia; A Nath; N Sacktor; C Anderson; C M Marra; D B Clifford
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.